155 related articles for article (PubMed ID: 1854508)
1. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Oberg K; Norheim I; Theodorsson E
Acta Oncol; 1991; 30(4):503-7. PubMed ID: 1854508
[TBL] [Abstract][Full Text] [Related]
2. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.
Wiedenmann B; Räth U; Rädsch R; Becker F; Kommerell B
Klin Wochenschr; 1988 Jan; 66(2):75-7. PubMed ID: 2894481
[TBL] [Abstract][Full Text] [Related]
4. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.
Welin SV; Janson ET; Sundin A; Stridsberg M; Lavenius E; Granberg D; Skogseid B; Oberg KE; Eriksson BK
Eur J Endocrinol; 2004 Jul; 151(1):107-12. PubMed ID: 15248829
[TBL] [Abstract][Full Text] [Related]
5. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms.
Ahlman H; Tisell LE
Scand J Gastroenterol; 1987 Oct; 22(8):938-42. PubMed ID: 2891186
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of carcinoid tumor with a long-acting somatostatin analog].
Werling K; Lengyel G; Fehér E; Jakab Z; Besznyák I; Feher J
Orv Hetil; 1993 Feb; 134(6):301-5. PubMed ID: 8430017
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
[TBL] [Abstract][Full Text] [Related]
9. Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.
Balks HJ; Conlon JM; Creutzfeldt W; Stöckmann F
Eur J Clin Pharmacol; 1989; 36(2):133-7. PubMed ID: 2470592
[TBL] [Abstract][Full Text] [Related]
10. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
12. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
[TBL] [Abstract][Full Text] [Related]
13. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
Rohaizak M; Farndon JR
ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A as a determinant of midgut carcinoid tumour volume.
Kölby L; Bernhardt P; Swärd C; Johanson V; Ahlman H; Forssell-Aronsson E; Stridsberg M; Wängberg B; Nilsson O
Regul Pept; 2004 Aug; 120(1-3):269-73. PubMed ID: 15177946
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.
Roti E; Minelli R; Gardini E; Salvi M; Bianconi L; Balducci L; Manfredi A; Braverman LE
J Endocrinol Invest; 1990 Jan; 13(1):69-72. PubMed ID: 2319110
[TBL] [Abstract][Full Text] [Related]
17. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
18. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
Tomassetti P; Migliori M; Corinaldesi R; Gullo L
Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
[TBL] [Abstract][Full Text] [Related]
19. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
Leong WL; Pasieka JL
J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
[TBL] [Abstract][Full Text] [Related]
20. Sandostatin and carcinoid tumours in France: experience in the Lyon area.
Chayvialle JA
Digestion; 1990; 45 Suppl 1():23-6. PubMed ID: 1692295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
